Abstract
Abstract
Objectives
In response to the controversy surrounding observational studies of the association between lipid profiles and the risk of insomnia, the aim of this study was to analyze lipid profiles, including triglycerides (TG), apolipoprotein A-1 (ApoA-1), apolipoprotein B (ApoB) and lipoprotein A (LPA), in a European population to further assess the causal relationship between these lipid types and insomnia.
Materials and methods
This study explores the causal effect of lipid profiles on insomnia based on a genome-wide association study (GWAS)-derived public dataset using two-sample and multivariate Mendelian randomization (MVMR) analysis. The main MR analyses used inverse variance weighting (IVW) odds ratio (OR), and the sensitivity analyses included weighted median (WM) and MR‒Egger.
Results
Both MR and MVMR showed that lowering ApoA-1 and LPA levels had causal effects on the risk of insomnia [MR: per 10 units, ApoA-1: OR: 0.7546, 95% CI: 0.6075–0.9372, P = 0.011; LPA: OR: 0.8392, 95% CI: 0.7202–0.9778, P = 0.025; MVMR: per 10 units, ApoA-1: OR: 0.7600, 95% CI: 0.6362–0.9079, P = 0.002; LPA, OR: 0.903, 95% CI: 0.8283–0.9845, P = 0.021]. There were no causal effects of TG or ApoB on insomnia (all P > 0.05). The MR‒Egger intercept test, funnel plot, and IVW methods all suggested an absence of strong directional pleiotropy, and leave-one-out permutation analysis did not detect any single single-nucleotide polymorphism that had a strong influence on the results.
Conclusion
Elevated levels of ApoA-1 and LPA were independently and causally associated with the risk of insomnia, suggesting that elevated ApoA-1 and LPA levels may contribute to a reduced risk of insomnia.
Funder
Wuhan Municipal Commission of Health and Family Planning Fund Progect
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics
Reference71 articles.
1. Perlis ML, Posner D, Riemann D, et al. Insomnia[J] Lancet. 2022;400(10357):1047–60.
2. Morin CM, Drake CL, Harvey AG, et al. Insomnia disorder[J]. Nat Rev Dis Primers. 2015;1:15026.
3. Lou BX, Oks M, Insomnia. Pharmacologic Treatment[J]. Clin Geriatr Med. 2021;37(3):401–15.
4. Matheson E, Hainer BL, Insomnia. Pharmacologic Therapy[J]. Am Fam Physician. 2017;96(1):29–35.
5. Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia[J]. Chest. 2015;147(4):1179–92.